<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32221906</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2240-2993</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta neurologica Belgica</Title><ISOAbbreviation>Acta Neurol Belg</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis with coexisting cancer: a single-center study.</ArticleTitle><Pagination><StartPage>1123</StartPage><EndPage>1130</EndPage><MedlinePgn>1123-1130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13760-020-01337-y</ELocationID><Abstract><AbstractText>This study investigated the occurrence of malignancy in a cohort of patients with amyotrophic lateral sclerosis (ALS). Forty-three consecutive ALS patients (mean age 61.3&#xa0;years, 31 men/12 women) admitted between 2015 and 2019 were enrolled. Clinical, electrophysiologic and outcome features that differentiate cancer-associated ALS from classical ALS were investigated. ALS was associated with cancer in 5 (11.6%) patients. Two patients were diagnosed with non-small cell lung, one with endometrium, one with prostate and one with laryngeal carcinoma. One another patient was diagnosed with monoclonal gammopathy of unknown significance, but she did not develop cancer within 12-month follow-up duration. Two patients had a previous diagnosis of cancer before the diagnosis of ALS. In the remaining 3 patients, cancer was diagnosed at the same time or after the onset of ALS. There was no significant difference with respect to mean age of onset, sex, disease duration, clinical and electrophysiological features and outcome between patients with and without malignancy. None of the patients with cancer survived more than two years after the onset of ALS except one who was diagnosed with flail-leg syndrome before the diagnosis of non-small cell lung carcinoma. ALS is not accepted as a classical paraneoplastic neurological syndrome. Although the association of ALS and cancer seems coincidental, a careful investigation for an underlying cancer is important in patients with ALS. In our patient group with cancer-associated ALS, no distinguishing features were identified.</AbstractText><CopyrightInformation>&#xa9; 2020. Belgian Neurological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akan</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Neurology Department, Okmeydani Training and Research Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baysal-Kirac</LastName><ForeName>Leyla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Department, Trakya University Hospital, Edirne, Turkey. baysalleyla@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Acta Neurol Belg</MedlineTA><NlmUniqueID>0247035</NlmUniqueID><ISSNLinking>0300-9009</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007822" MajorTopicYN="N">Laryngeal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Paraneoplastic disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32221906</ArticleId><ArticleId IdType="doi">10.1007/s13760-020-01337-y</ArticleId><ArticleId IdType="pii">10.1007/s13760-020-01337-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raymond J, Oskarsson B, Mehta P, Horton K (2019) Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010&#x2013;2015. Amyotroph Lateral Scler Frontotemporal Degener 20:413&#x2013;420</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1612435</ArticleId></ArticleIdList></Reference><Reference><Citation>Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, Euronetwork PNS (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67:330&#x2013;335</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson SB, Abbott D, Farnham JM, Thai KK, McLean H, Figueroa KP et al (2016) Population-based risks for cancer in patients with ALS. Neurology 87:289&#x2013;294</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002757</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB (1997) Motor neuron syndromes in cancer patients. Ann Neurol 41:722&#x2013;730</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadot E, Carluer L, Corcia P, Delozier Y, Levy C, Viader F (2007) Breast cancer and motor neuron disease: clinical study of seven cases. Amyotroph Lateral Scler 8:288&#x2013;291</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701419505</ArticleId></ArticleIdList></Reference><Reference><Citation>Spataro R, La Bella V (2014) Paraneoplastic motor neuron disease associated with breast cancer. Eur J Neurol 21:e5&#x2013;6</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12295</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;l&#xe9; N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N et al (2018) Motor neuron disease of paraneoplastic origin: a rare but treatable condition. J Neurol 265:1590&#x2013;1599</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8881-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan EP, Sandroni P, Pittock SJ, Inwards DJ, Jones LK Jr (2012) Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma. Muscle Nerv 46:823&#x2013;827</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23464</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschueren A, Gallard J, Boucraut J, Honnorat J, Pouget J, Attarian S (2015) Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. J Neurol Sci 358:413&#x2013;416</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J et al (2009) Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72:1087&#x2013;1094</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000345041.83406.a2</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo-Monachelli GM, Janota F, Bettini M, Shoesmith CL, Strong MJ, Sica RE (2012) Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 19:834&#x2013;841</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03616.x</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119:497&#x2013;503</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group [Phase III]. J Neurol Sci 169:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Drory VE (2013) Postradiation lower motor neuron syndrome: case series and literature review. J Neurol 260:1802&#x2013;1806</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-6881-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz FG, Bekircan-Kurt CE, Varli K (2017) Single-pulse transcranial magnetic stimulation in amyotrophic lateral sclerosis: experience of a single institution. Neurol Sci Neurophysiol 34:70&#x2013;75</Citation></Reference><Reference><Citation>Vigliani MC, Polo P, Chi&#xf2; A, Giometto B, Mazzini L, Schiffer D (2000) Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. J Neurology 247:778&#x2013;782</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150070092</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Bustani N, Simonson W, Marshall DA, Vetrovs J, Wener MH, Weiss MD et al (2015) Utility of paraneoplastic antibody testing in the diagnosis of motor neuron disease. J Clin Neuromuscul Dis 17:63&#x2013;68</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000080</ArticleId></ArticleIdList></Reference><Reference><Citation>Stich O, Kleer B, Rauer S (2007) Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease. J Neuro Neurosurg Psychiatry 78:883&#x2013;885</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.097774</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis; Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis [MALS]&#x2014;revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;375</Citation></Reference><Reference><Citation>Corcia P, Gordon PH, Camdessanche JP (2015) Is there a paraneoplastic ALS? Amyotroph Lateral Scler Frontotemporal Degener 16:252&#x2013;257</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.965178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Al-Chalabi A, Ronnevi LO, Turner MR, Wirdefeldt K, Kamel F, Ye W (2013) Amyotrophic lateral sclerosis and cancer: a register-based study in Sweden. Amyotroph Lateral Sclerosis Frontotemporal Degener 14:362&#x2013;368</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.775309</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Curtis RE, Daugherty SE, Goedert JJ, Kuncl RW, Tucker MA (2013) The association between cancer and amyotrophic lateral sclerosis. Cancer Causes Control 24:55&#x2013;60</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-012-0089-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, Berger JR, Snodgrass S, Petito C (1996) Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 40:112&#x2013;116</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400118</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Rowland LP, Younger DS, Sherman WH, Hays AP, Louis ED (1997) Lymphoproliferative disorders and motor neuron disease: an update. Neurology 48:1671&#x2013;1678</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.6.1671</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman D, Rae-Grant AD, Matchett SC, Cowen JS (1999) A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Chest 115:899&#x2013;901</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.115.3.899</ArticleId></ArticleIdList></Reference><Reference><Citation>Distad BJ, Weiss MD (2010) Paraneoplastic motor neuron disease associated with Purkinje cell autoantibody type 1. J Clin Neuromuscul Dis 12:36&#x2013;41</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0b013e3181c50528</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamanti L, Quaquarini E, Berzero G, Bini P, Gastaldi M, Franciotta D et al (2018) Lower motor neuron syndrome in a patient with HER2-positive metastatic breast cancer: a case report and review of the literature. Clin Neurol Neurosurg 172:141&#x2013;142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2018.06.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoine JC, Camdessanch&#xe9; JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30:513&#x2013;520</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000475</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoine JC (2014) Peripheral neuropathies associated with antibodies directed to intracellular neural antigens. Rev Neurol [Paris] 170:570&#x2013;576</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2014.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchuya M, Graus F, Vega F, Re&#xf1;&#xe9; R, Delattre JY (1996) Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 60:388&#x2013;392</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.60.4.388</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SJ, Dropcho EJ, Claussen GC (1997) Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 20:1576&#x2013;1582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199712)20:12&lt;1576::AID-MUS13&gt;3.0.CO;2-Z</ArticleId></ArticleIdList></Reference><Reference><Citation>Keime-Guibert F, Graus F, Fleury A, Ren&#xe9; R, Honnorat J, Broet P et al (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies [anti-Hu, anti-Yo] with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68:479&#x2013;482</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.68.4.479</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van't Veer M et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16&#x2013;20</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-005-0882-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Giometto B, Vitaliani R, Lindeck-Pozza E, Grisold W, Vedeler C (2012) Treatment for paraneoplastic neuropathies. Cochrane Database Syst Rev 12:CD007625</Citation><ArticleIdList><ArticleId IdType="pubmed">23235647</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135&#x2013;1140</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheli M, Dinoto A, Ridolfi M, Sartori A, Stokelj D, Manganotti P (2019) Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. J Neurol Sci 15(400):158&#x2013;159</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.03.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow J, Gorrie G, Leach V, Patel S, Mackay G (2019) Cancer and motor neuron disease-causal or coincidental? Two contrasting cases. Neurol Sci 40:1461&#x2013;1463</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03784-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Struck AF, Salamat S, Waclawik AJ (2014) Motor neuron disease with selective degeneration of anterior horn cells associated with non-Hodgkin lymphoma. J Clin Neuromuscul Dis 16:83&#x2013;89</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>